Shinsuke Iida

14.9k total citations
331 papers, 7.8k citations indexed

About

Shinsuke Iida is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Shinsuke Iida has authored 331 papers receiving a total of 7.8k indexed citations (citations by other indexed papers that have themselves been cited), including 185 papers in Hematology, 131 papers in Molecular Biology and 112 papers in Oncology. Recurrent topics in Shinsuke Iida's work include Multiple Myeloma Research and Treatments (157 papers), Protein Degradation and Inhibitors (61 papers) and Peptidase Inhibition and Analysis (51 papers). Shinsuke Iida is often cited by papers focused on Multiple Myeloma Research and Treatments (157 papers), Protein Degradation and Inhibitors (61 papers) and Peptidase Inhibition and Analysis (51 papers). Shinsuke Iida collaborates with scholars based in Japan, United States and Spain. Shinsuke Iida's co-authors include Ryuzo Ueda, Hirokazu Komatsu, Takashi Ishida, Shigeru Kusumoto, Hiroshi Inagaki, Masaki Ri, Atsushi Inagaki, Riccardo Dalla‐Favera, Atae Utsunomiya and Asahi Ito and has published in prestigious journals such as Nature Communications, Nature Genetics and Journal of Clinical Oncology.

In The Last Decade

Shinsuke Iida

312 papers receiving 7.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Shinsuke Iida Japan	46	3.0k	2.7k	2.7k	2.2k	1.5k	331	7.8k
HP Koeffler United States	44	3.1k 1.0×	1.8k 0.7×	1.6k 0.6×	2.0k 0.9×	898 0.6×	90	6.5k
Hitoshi Kiyoi Japan	46	4.4k 1.4×	2.1k 0.8×	1.2k 0.5×	5.4k 2.4×	782 0.5×	277	9.0k
Justus Duyster Germany	52	3.9k 1.3×	2.4k 0.9×	1.5k 0.6×	3.5k 1.6×	1.3k 0.8×	261	9.0k
Mariusz A. Wasik United States	55	3.2k 1.0×	4.9k 1.8×	3.4k 1.3×	1.1k 0.5×	3.0k 1.9×	187	10.4k
Martin Sattler United States	55	4.3k 1.4×	2.4k 0.9×	1.2k 0.5×	3.1k 1.4×	563 0.4×	151	8.6k
Veronika Sexl Austria	51	3.3k 1.1×	3.6k 1.3×	4.4k 1.7×	1.5k 0.7×	717 0.5×	183	9.5k
Oliver G. Ottmann Germany	62	4.9k 1.6×	4.0k 1.5×	2.4k 0.9×	10.4k 4.6×	882 0.6×	372	16.1k
R. Eric Davis United States	46	3.8k 1.2×	2.6k 1.0×	2.7k 1.0×	1.3k 0.6×	2.4k 1.6×	161	8.4k
David A. Rizzieri United States	44	3.0k 1.0×	2.5k 0.9×	1.6k 0.6×	4.3k 1.9×	916 0.6×	309	8.1k
Bayard Clarkson United States	22	1.5k 0.5×	1.8k 0.7×	538 0.2×	1.9k 0.8×	385 0.3×	43	4.9k

Countries citing papers authored by Shinsuke Iida

Since Specialization

Citations

This map shows the geographic impact of Shinsuke Iida's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shinsuke Iida with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shinsuke Iida more than expected).

Fields of papers citing papers by Shinsuke Iida

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shinsuke Iida. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shinsuke Iida. The network helps show where Shinsuke Iida may publish in the future.

Co-authorship network of co-authors of Shinsuke Iida

This figure shows the co-authorship network connecting the top 25 collaborators of Shinsuke Iida. A scholar is included among the top collaborators of Shinsuke Iida based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shinsuke Iida. Shinsuke Iida is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Iida, Shinsuke, Yevgeniy Samyshkin, Chi‐Chang Chen, et al.. (2025). Characteristics and treatment patterns in patients with multiple myeloma in Japan: A retrospective cohort analysis. PLoS ONE. 20(1). e0315932–e0315932. 2 indexed citations

Suzuki, Tomotaka, Ryunosuke Machida, Kazuyuki Shimada, et al.. (2025). Prognostic impact of RDI of vincristine in patients with DLBCL receiving R-CHOP: a supplementary analysis of JCOG0601. PubMed. 2(2). 100077–100077.

Suzuki, Tomotaka, Aki Kondo, Shiori Kinoshita, et al.. (2024). Clinical Significance of Cytomegalovirus Reactivation in Patients With Plasma Cell Dyscrasia Who Were Treated With Anti-CD38 Monoclonal Antibody: A Retrospective Analysis in a Single Institution. Clinical Lymphoma Myeloma & Leukemia. 24(8). 531–536.e1. 2 indexed citations

Pianko, Matthew J., Charlotte Pawlyn, Shang‐Yi Huang, et al.. (2024). MagnetisMM-9: Efficacy and Safety of Step-up Priming Doses and Longer Dosing Intervals of Elranatamab (ELRA) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM). Blood. 144(Supplement 1). 4743–4743.

Fukushima, Takuya, Kunihiro Tsukasaki, Ryunosuke Machida, et al.. (2024). Upfront allo-HSCT after intensive chemotherapy for untreated aggressive ATL: JCOG0907, a single-arm, phase 3 trial.. Journal of Clinical Oncology. 42(16_suppl). 7001–7001. 1 indexed citations

Ishida, Tadao, et al.. (2023). Evaluating process utilities for the treatment burden of chemotherapy in multiple myeloma in Japan: a time trade-off valuation study. Journal of Medical Economics. 26(1). 565–573. 1 indexed citations

Maeda, Yuka, Hisashi Wada, Daisuke Sugiyama, et al.. (2021). Depletion of central memory CD8+ T cells might impede the antitumor therapeutic effect of Mogamulizumab. Nature Communications. 12(1). 7280–7280. 29 indexed citations

Dimopoulos, Meletios Α., S. Vincent Rajkumar, Sagar Lonial, et al.. (2021). Interim Analyses of Overall Survival (OS) from the TOURMALINE MM3 & MM4 Studies of Ixazomib Maintenance Following Primary Therapy in Multiple Myeloma (MM). Blood. 138(Supplement 1). 1656–1656. 2 indexed citations

Ishii, Toshihiko, Itaru Urakawa, Ayako Masaki, et al.. (2019). Mogamulizumab Treatment Elicits Autoantibodies Attacking the Skin in Patients with Adult T-Cell Leukemia-Lymphoma. Clinical Cancer Research. 25(14). 4388–4399. 20 indexed citations

10.

Iida, Shinsuke, Takashi Watanabe, Morio Matsumoto, et al.. (2019). Carfilzomib monotherapy in Japanese patients with relapsed or refractory multiple myeloma: A phase 1/2 study. Cancer Science. 110(9). 2924–2932. 6 indexed citations

11.

Maruyama, Dai, et al.. (2018). Weekly carfilzomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma: A phase 1 and PK/PD trial. Cancer Science. 109(10). 3245–3252. 6 indexed citations

12.

Masaki, Ayako, Takashi Ishida, Yasuhiro Maeda, et al.. (2017). Clinical significance of tryptophan catabolism in Hodgkin lymphoma. Cancer Science. 109(1). 74–83. 22 indexed citations

13.

Masaki, Ayako, Takashi Ishida, Yasuhiro Maeda, et al.. (2015). Prognostic Significance of Tryptophan Catabolism in Adult T-cell Leukemia/Lymphoma. Clinical Cancer Research. 21(12). 2830–2839. 42 indexed citations

14.

Kurose, Koji, Yoshihiro Ohue, Hisashi Wada, et al.. (2015). Phase Ia Study of FoxP3+ CD4 Treg Depletion by Infusion of a Humanized Anti-CCR4 Antibody, KW-0761, in Cancer Patients. Clinical Cancer Research. 21(19). 4327–4336. 179 indexed citations

15.

Yoshida, Tatsuya, Genichiro Ishii, Kōichi Goto, et al.. (2014). Podoplanin-Positive Cancer-Associated Fibroblasts in the Tumor Microenvironment Induce Primary Resistance to EGFR-TKIs in Lung Adenocarcinoma with EGFR Mutation. Clinical Cancer Research. 21(3). 642–651. 102 indexed citations

16.

Chinen, Yoshiaki, Junya Kuroda, Yuji Shimura, et al.. (2014). Phosphoinositide Protein Kinase PDPK1 Is a Crucial Cell Signaling Mediator in Multiple Myeloma. Cancer Research. 74(24). 7418–7429. 28 indexed citations

17.

Shimura, Yuji, Junya Kuroda, Masaki Ri, et al.. (2012). RSK2Ser227 at N-Terminal Kinase Domain Is a Potential Therapeutic Target for Multiple Myeloma. Molecular Cancer Therapeutics. 11(12). 2600–2609. 28 indexed citations

18.

Nakao, Makoto, Keitaro Matsuo, Hidemi Ito, et al.. (2011). ABO Genotype and the Risk of Gastric Cancer, Atrophic Gastritis, and Helicobacter pylori Infection. Cancer Epidemiology Biomarkers & Prevention. 20(8). 1665–1672. 54 indexed citations

19.

Ito, Asahi, Takashi Ishida, Hiroki Yano, et al.. (2008). Defucosylated anti-CCR4 monoclonal antibody exercises potent ADCC-mediated antitumor effect in the novel tumor-bearing humanized NOD/Shi-scid, IL-2Rγnull mouse model. Cancer Immunology Immunotherapy. 58(8). 1195–1206. 96 indexed citations

20.

Ding, Jianmin, Hirokazu Komatsu, Atsushi Wakita, et al.. (2004). Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin. Blood. 103(11). 4198–4200. 234 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact